To systematically evaluate the clinical value of angiogenesis inhibitors in neoadjuvant chemotherapy (NACT) for breast cancer.
Approach:
Search Methodology: Systematically searched PubMed and Web of Science databases up to July 16, 2025, to identify randomized controlled trials (RCTs) comparing angiogenesis inhibitor-based NACT regimens with angiogenesis inhibitor-free regimens.
Statistical Analysis: Used random effects models to calculate pooled odds ratios and hazard ratios with 95% confidence intervals for pathological complete response (pCR), disease-free survival (DFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs).
Key Findings:
NACT containing angiogenesis inhibitors significantly increased the pCR rate (22.59% vs. 29.88%).
No statistically significant improvement in pCR among hormone receptor-positive patients.
In triple-negative breast cancer (TNBC), the pCR rate was significantly elevated (32.42% vs. 42.46%).
No significant differences observed in DFS or OS.
Interpretation:
Current research does not support an improvement in OS, and there is a lack of clear biomarkers for predicting treatment efficacy.
Limitations:
Current research has not reached a consensus on whether the combination improves overall survival.
Lack of clear biomarkers for predicting treatment efficacy.
Conclusion:
The findings indicate that combining angiogenesis inhibitors with NACT may enhance treatment response in TNBC.
